Evidence map›Paper›PMID 36745193›Full record

ArticleAnnals of hematology2023

Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia.

Tongtong Zhang, Haixia Zhou, Mingzhu Xu, Chongsheng Qian, Aining Sun, Depei Wu, Shengli Xue

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tongtong ZhangJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.ORCID http://orcid.org/0000-0003-0866-1797
Haixia ZhouJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Mingzhu XuJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Chongsheng QianJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Aining SunJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Depei WuJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
Shengli XueJiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China. slxue@suda.edu.cn.

Funding

Gusu Key Medical Talent Program GSWS2019007National Natural Science Foundation of China 81900130National Natural Science Foundation of China 81970138Social Development Project of the Science and Technology Department of Jiangsu BE2021649Translational Research Grant of NCRCH 2020ZKMB05
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, MyeloidLeukemia, Myeloid, AcuteAlkynesAntineoplastic Combined Chemotherapy ProtocolsBenzamidesBlast CrisisBridged Bicyclo Compounds, HeterocyclicHumansPiperidinesPyrazolesPyridinesSulfonamidesAlkynesBenzamidesBridged Bicyclo Compounds, HeterocyclicolverembatinibPiperidinesPyrazolesPyridinesSulfonamidesvenetoclax

Identifiers

PMID36745193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.